Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.

Xu Y, Taylor P, Andrade J, Ueberheide B, Shuch B, Glazer PM, Bindra RS, Moran MF, Linehan WM, Neel BG.

Cancer Res. 2018 Oct 8. pii: canres.0901.2018. doi: 10.1158/0008-5472.CAN-18-0901. [Epub ahead of print]

PMID:
30297534
2.

Determinants of Active Surveillance in Patients with Small Renal Masses.

Nguyen KA, Nolte AC, Alimi O, Hsiang W, Lu AJ, Ghabili K, Syed JS, Suarez-Sarmiento A, Perecman AJ, Shuch B, Leapman MS.

Urology. 2018 Jul 27. pii: S0090-4295(18)30772-6. doi: 10.1016/j.urology.2018.07.021. [Epub ahead of print]

PMID:
30059717
3.

Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis.

Callahan CL, Hofmann JN, Corley DA, Zhao WK, Shuch B, Chow WH, Purdue MP.

Cancer Epidemiol. 2018 Oct;56:31-37. doi: 10.1016/j.canep.2018.07.002. Epub 2018 Jul 18.

PMID:
30029068
4.

Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.

Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM.

Nat Genet. 2018 Aug;50(8):1086-1092. doi: 10.1038/s41588-018-0170-4. Epub 2018 Jul 16.

PMID:
30013182
5.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

6.

Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials.

Wilkins JF, Cannataro VL, Shuch B, Townsend JP.

Oncotarget. 2018 Apr 27;9(32):22243-22253. doi: 10.18632/oncotarget.25155. eCollection 2018 Apr 27.

7.

Genomic Heterogeneity and the Small Renal Mass.

Ueno D, Xie Z, Boeke M, Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey P, Dancik GM, Kluger Y, Liu Z, Kluger H, Shuch B.

Clin Cancer Res. 2018 Sep 1;24(17):4137-4144. doi: 10.1158/1078-0432.CCR-18-0214. Epub 2018 May 14.

PMID:
29760223
8.

Genetic testing for hereditary prostate cancer: Current status and limitations.

Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B.

Cancer. 2018 Aug 1;124(15):3105-3117. doi: 10.1002/cncr.31316. Epub 2018 Apr 18. Review.

PMID:
29669169
9.

The Cell Cycle Progression Score: Unclear Role in Renal Cell Carcinoma.

Ueno D, Dancik GM, Shuch B.

Eur Urol. 2018 Jul;74(1):128-129. doi: 10.1016/j.eururo.2018.03.033. Epub 2018 Apr 13. No abstract available.

PMID:
29661484
10.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. Erratum in: Cell Rep. 2018 Jun 19;23(12):3698.

11.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

12.

Survival outcomes for patients with localised upper tract urothelial carcinoma managed with non-definitive treatment.

Syed JS, Nguyen KA, Suarez-Sarmiento A, Johnson K, Leapman MS, Raman JD, Shuch B.

BJU Int. 2018 Jan;121(1):124-129. doi: 10.1111/bju.14042. Epub 2017 Oct 29.

PMID:
28972702
13.

Optimizing waiting duration for renal transplants in the setting of renal malignancy: is 2 years too long to wait?

Nguyen KA, Syed JS, Luciano R, Shuch B, Vourganti S.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1767-1773. doi: 10.1093/ndt/gfx254.

14.

Ethnic disparities in renal cell carcinoma: An analysis of Hispanic patients in a single-payer healthcare system.

Suarez-Sarmiento A, Yao X, Hofmann JN, Syed JS, Zhao WK, Purdue MP, Chow WH, Corley D, Shuch B.

Int J Urol. 2017 Oct;24(10):765-770. doi: 10.1111/iju.13424. Epub 2017 Sep 15.

15.

Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test.

Nguyen KA, Syed JS, Espenschied CR, LaDuca H, Bhagat AM, Suarez-Sarmiento A, O'Rourke TK Jr, Brierley KL, Hofstatter EW, Shuch B.

Cancer. 2017 Nov 15;123(22):4363-4371. doi: 10.1002/cncr.30893. Epub 2017 Aug 8.

PMID:
28787086
16.

Leukocyte telomere length and renal cell carcinoma survival in two studies.

Callahan CL, Schwartz K, Ruterbusch JJ, Shuch B, Graubard BI, Lan Q, Cawthon R, Baccarelli AA, Chow WH, Rothman N, Hofmann JN, Purdue MP.

Br J Cancer. 2017 Aug 22;117(5):752-755. doi: 10.1038/bjc.2017.237. Epub 2017 Jul 25.

17.

Current Treatment Landscape of Advanced Papillary Renal Cancer.

Shuch B, Hahn AW, Agarwal N.

J Clin Oncol. 2017 Sep 10;35(26):2981-2983. doi: 10.1200/JCO.2017.74.3328. Epub 2017 Jul 24. No abstract available.

PMID:
28737973
18.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
19.

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2017 Jun;15(6):804-834. doi: 10.6004/jnccn.2017.0100.

PMID:
28596261
20.

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.

Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH.

Eur Urol. 2018 Jan;73(1):71-78. doi: 10.1016/j.eururo.2017.05.033. Epub 2017 Jun 4.

PMID:
28592388
21.

Adverse pathologic characteristics in the small renal mass: implications for active surveillance.

Syed JS, Nawaf CB, Rosoff J, Bryson C, Nguyen KA, Suarez-Sarmiento A, Serrano M, Kibel AS, Humphrey P, Shuch B, Adeniran AJ.

Can J Urol. 2017 Apr;24(2):8759-8764.

22.

Hereditary Kidney Cancer Syndromes and Surgical Management of the Small Renal Mass.

Nguyen KA, Syed JS, Shuch B.

Urol Clin North Am. 2017 May;44(2):155-167. doi: 10.1016/j.ucl.2016.12.002. Epub 2017 Mar 14. Review.

PMID:
28411908
23.

End-stage renal disease secondary to renal malignancy: Epidemiologic trends and survival outcomes.

Nguyen KA, Vourganti S, Syed JS, Luciano R, Campbell SC, Shuch B.

Urol Oncol. 2017 Aug;35(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2017.03.003. Epub 2017 Mar 28.

PMID:
28363473
24.

Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations.

Li S, Shuch BM, Gerstein MB.

PLoS Genet. 2017 Mar 30;13(3):e1006685. doi: 10.1371/journal.pgen.1006685. eCollection 2017 Mar.

25.

Distinguishing pediatric and adolescent renal cell carcinoma from other renal malignancies.

Syed JS, Nguyen KA, Wu CQ, Cost NG, Siddiqui MM, Hittelman AB, Shuch B.

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26315. Epub 2016 Nov 2.

PMID:
27805307
26.

MET Inhibition in Clear Cell Renal Cell Carcinoma.

Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B.

J Cancer. 2016 Jun 18;7(10):1205-14. doi: 10.7150/jca.14604. eCollection 2016.

27.

Management of renal cell carcinoma in young patients and patients with hereditary syndromes.

Leung C, Pan S, Shuch B.

Curr Opin Urol. 2016 Sep;26(5):396-404. doi: 10.1097/MOU.0000000000000322. Review.

PMID:
27387961
28.

Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma.

Agarwal N, Shuch B, Pal SK.

JAMA Oncol. 2016 Oct 1;2(10):1273-1274. doi: 10.1001/jamaoncol.2016.1198. No abstract available.

PMID:
27254305
29.

Racial disparities in renal cell carcinoma: a single-payer healthcare experience.

Mafolasire A, Yao X, Nawaf C, Suarez-Sarmiento A, Chow WH, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B.

Cancer Med. 2016 Aug;5(8):2101-8. doi: 10.1002/cam4.755. Epub 2016 May 26.

30.

Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.

Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ.

Cell Rep. 2016 Mar 15;14(10):2476-89. doi: 10.1016/j.celrep.2016.02.024. Epub 2016 Mar 3.

31.

Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.

Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P.

Oncotarget. 2016 Mar 15;7(11):12975-96. doi: 10.18632/oncotarget.7349.

32.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

33.

Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features.

Adeniran AJ, Shuch B, Humphrey PA.

Am J Surg Pathol. 2015 Dec;39(12):e1-e18. doi: 10.1097/PAS.0000000000000562. Review.

PMID:
26559379
34.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R.

N Engl J Med. 2016 Jan 14;374(2):135-45. doi: 10.1056/NEJMoa1505917. Epub 2015 Nov 4.

35.

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.

Shuch B, Falbo R, Parisi F, Adeniran A, Kluger Y, Kluger HM, Jilaveanu LB.

Biomed Res Int. 2015;2015:192406. doi: 10.1155/2015/192406. Epub 2015 Sep 13.

36.

Testicular Cancer, Version 2.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2015 Jun;13(6):772-99.

PMID:
26085393
37.

Seminoma in Cryptorchid Testis in Prune Belly Syndrome.

Humphrey PA, Shuch B.

J Urol. 2015 Sep;194(3):799-800. doi: 10.1016/j.juro.2015.06.015. Epub 2015 Jun 6. No abstract available.

PMID:
26057338
38.

The authors respond.

Hofmann JN, Corley DA, Colt JS, Shuch B, Chow WH, Purdue MP.

Epidemiology. 2015 Jul;26(4):e49. doi: 10.1097/EDE.0000000000000305. No abstract available.

39.

Kidney cancer, version 3.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Feb;13(2):151-9.

PMID:
25691606
40.

Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes.

Martucci VL, Lorenzo ZG, Weintraub M, del Rivero J, Ling A, Merino M, Siddiqui M, Shuch B, Vourganti S, Linehan WM, Agarwal PK, Pacak K.

Urol Oncol. 2015 Apr;33(4):167.e13-20. doi: 10.1016/j.urolonc.2014.11.017. Epub 2015 Feb 13.

41.

Chronic kidney disease and risk of renal cell carcinoma: differences by race.

Hofmann JN, Corley DA, Zhao WK, Colt JS, Shuch B, Chow WH, Purdue MP.

Epidemiology. 2015 Jan;26(1):59-67. doi: 10.1097/EDE.0000000000000205.

42.

PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.

J Clin Pathol. 2015 Jan;68(1):12-7. doi: 10.1136/jclinpath-2014-202259. Epub 2014 Oct 14.

43.

The somatic genomic landscape of chromophobe renal cell carcinoma.

Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA; The Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ.

Cancer Cell. 2014 Sep 8;26(3):319-330. doi: 10.1016/j.ccr.2014.07.014. Epub 2014 Aug 21.

44.

Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.

Shuch B, Agochukwu N, Ricketts CJ, Vocke CD, Gautam R, Merino M, Linehan WM, Srinivasan R.

J Clin Oncol. 2016 Mar 20;34(9):e76-9. doi: 10.1200/JCO.2013.51.0214. Epub 2014 Jul 14. No abstract available.

PMID:
25024072
45.

Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.

Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A.

Eur Urol. 2015 Jan;67(1):85-97. doi: 10.1016/j.eururo.2014.04.029. Epub 2014 May 21. Review.

PMID:
24857407
46.

Clinical management of renal cell carcinoma with venous tumor thrombus.

Agochukwu N, Shuch B.

World J Urol. 2014 Jun;32(3):581-9. doi: 10.1007/s00345-014-1276-7. Epub 2014 Apr 22. Review.

PMID:
24752606
47.

The genetic basis of pheochromocytoma and paraganglioma: implications for management.

Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM.

Urology. 2014 Jun;83(6):1225-32. doi: 10.1016/j.urology.2014.01.007. Epub 2014 Mar 15. Review.

48.

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.

Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM.

J Cancer. 2014 Jan 24;5(3):166-72. doi: 10.7150/jca.8167. eCollection 2014.

49.

A nested case-control study of leukocyte mitochondrial DNA copy number and renal cell carcinoma in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Hofmann JN, Hosgood HD 3rd, Liu CS, Chow WH, Shuch B, Cheng WL, Lin TT, Moore LE, Lan Q, Rothman N, Purdue MP.

Carcinogenesis. 2014 May;35(5):1028-31. doi: 10.1093/carcin/bgt495. Epub 2014 Jan 7.

50.

Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.

Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.

J Clin Oncol. 2014 Feb 10;32(5):431-7. doi: 10.1200/JCO.2013.50.8192. Epub 2013 Dec 30.

Supplemental Content

Support Center